Trial Profile

A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MGD 014 (Primary)
Indications HIV-1 infections
Focus Adverse reactions
Sponsors MacroGenics

Most Recent Events

19 Oct 2021 Status changed from recruiting to completed.
26 Aug 2020 Planned End Date changed from 1 Mar 2020 to 1 Oct 2021.
26 Aug 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com